Votrient 200 and 400 mg FC tablets
PDF Leaflet Revision Date: 31 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced renal cell carcinoma and certain subtypes of soft tissue sarcoma.
Dosage (summary)
800 mg orally once daily, taken whole with water, without food.
Special Populations
- Elderly
- Moderate hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Can cause fetal harm; contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Simvastatin
- Grapefruit juice
Contraindications
- Hypersensitivity to pazopanib
Common side effects
- Hypertension
- Fatigue
- Nausea
- Diarrhea
- Hypothyroidism
Counselling Points
- Take without food
- Monitor liver function
- Use effective contraception
- Report signs of liver dysfunction
Serious warnings
- Hepatic failure
- Hypertensive crisis
- Cardiac dysfunction
- PRES/RPLS
- GI perforation
Important Disclaimer
The Votrient 200 and 400 mg FC tablets professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
